Skip to main content

Chimeric Antigen Receptor T-Cell Therapy

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

  • RegistryNCT06815029
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Glioblastoma
  • SponsorCity of Hope Medical Center
How Chimeric Antigen Receptor T-Cell Therapy worksNCT068150291 min

What the film says

Read the transcript

Glioblastoma almost always returns after surgery, radiation, and chemotherapy; at recurrence, nothing reliably extends life.

The idea: deliver engineered immune cells straight into the brain, and delete the switch the tumor uses to shut them down.

City of Hope has treated glioblastoma with CAR T cells aimed at IL13Rα2, a marker on most of these tumors, infused through a small catheter into the brain. Glioblastoma pours out TGF-beta, which quiets immune cells. Here, the gene for the TGF-beta receptor is knocked out of the T cells first, so the tumor's brake no longer works on them. Doses are given weekly for four weeks, then more if tolerated.

Behnam Badie leads the trial in Duarte. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06815029

    Glioblastoma recurs; recurrent disease lacks effective therapy; City of Hope prior IL13Rα2 CAR T program (IRB 13384); IL13Rα2 on most GBM; Intracranial delivery via Rickham catheter after resection (+3 more lines)

The drug

What is being tested.

Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially

PRIMARY OBJECTIVE: I. Assess the safety and determine the maximum tolerated dose (MTD) of intracranial (IC) administration of TGFβR2KO/IL13Rα2-CAR T cell therapy. SECONDARY OBJECTIVES: I. In participants who receive at least 50% of the assigned cell dose for each of the four cycles and at least 70% of the total cumulative dose for all cycles (1-4): Ia. Estimate overall response rates (ORR) and complete response (CR) rate at 3, 6, 9-months; and Ib.

Estimate overall survival (OS) at 9-months. II. Determine feasibility of IC administered TGFβR2KO/IL13Rα2-CAR T cell therapy as assessed by leukapheresis and manufacturing processes, including ability to meet the TGFβR2KO/IL13Rα2-CAR T cell dose and product release requirements; III. Determine the maximum feasible dose (MFD), as assessed by leukapheresis, manufacturing, toxicity, and response data. EXPLORATORY OBJECTIVES: I.

The study

How the trial runs.

This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive).

CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Documented informed consent of the participant and/or legally authorized representative
  • Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated main consent is processed. However, the research participant is allowed to proceed with surgery/Rickham placement and CAR T cell infusion only after the translated main consent form is signed
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Karnofsky performance status (KPS) ≥ 70%, Eastern Cooperative Oncology Group (ECOG) ≤ 2
  • Life expectancy ≥ 4 weeks
  • If the participant has a shunt, they must be informed of the following:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.